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Abstract
Introduction: Despite advances in early detection and adjuvant targeted therapies, breast cancer is still the second
most common cause of cancer mortality among women. Tumor recurrence is one of the major contributors to
breast cancer mortality. However, the mechanisms underlying this process are not completely understood. In this
study, we investigated the mechanisms of tumor dormancy and recurrence in a preclinical mouse model of breast
cancer.
Methods: To elucidate the mechanisms driving tumor recurrence, we employed a transplantable Wnt1/inducible
fibroblast growth factor receptor (FGFR) 1 mouse mammary tumor model and utilized an FGFR specific inhibitor,
BGJ398, to study the recurrence after treatment. Histological staining was performed to analyze the residual tumor
cells and tumor stroma. Reverse phase protein array was performed to compare primary and recurrent tumors to
investigate the molecular mechanisms leading to tumor recurrence.
Results: Treatment with BGJ398 resulted in rapid tumor regression, leaving a nonpalpable mass of dormant tumor
cells organized into a luminal and basal epithelial layer similar to the normal mammary gland, but surrounded by
dense stroma with markedly reduced levels of myeloid-derived tumor suppressor cells (MDSCs) and decreased
tumor vasculature. Following cessation of treatment the tumors recurred over a period of 1 to 4 months. The
recurrent tumors displayed dense stroma with increased collagen, tenascin-C expression, and MDSC infiltration.
Activation of the epidermal growth factor receptor (EGFR) pathway was observed in recurrent tumors, and
inhibition of EGFR with lapatinib in combination with BGJ398 resulted in a significant delay in tumor recurrence
accompanied by reduced stroma, yet there was no difference observed in initial tumor regression between the
groups treated with BGJ398 alone or in combination with lapatinib.
Conclusion: These studies have revealed a correlation between tumor recurrence and changes of stromal
microenvironment accompanied by altered EGFR signaling.
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Introduction
Tumor dormancy, a specific stage in cancer progression in
which residual disease is present but remains asymptom-
atic, has been a major issue in cancer research for many
years [1]. Possible mechanisms that have been suggested to
contribute to tumor dormancy include: insufficient angio-
genesis, an effective immune-suppressive response that
keeps the cancer cells in check, and crosstalk with cells or
proteins released in the microenvironment to arrest cancer
cells in G0 stage [2]. Dormant cells, remaining undetect-
able over a prolonged period of time after the initial treat-
ment, may exit from dormancy upon receiving stimuli,
such as growth factors, cytokines, nutrients, or chemical
agents, and re-enter the cell cycle to proliferate, eventually
resulting in a life-threatening recurrence.
The stromal microenvironment has been increasingly
recognized as a critical factor for cancer progression [1].
Changes in the stroma, which occur either during or after
treatment, may facilitate tumor recurrence [3, 4]. In breast
cancer, women with dense breasts detected by mammog-
raphy have a two- to sixfold increase in their susceptibility
to develop breast cancer [5] and breast cancers are
thought to most likely arise from these dense tissues [6].
In fact, mammographic density, comprising epithelial and
fibrous stromal tissues, is considered as a predictor of
breast cancer outcome [7]. Moreover, changes in expres-
sion of certain genes in the mammary stroma are predict-
ive markers in breast cancer pathogenesis [8–10]. Overall
these studies indicate that the stroma is strongly associ-
ated with breast cancer progression.
There is therefore a need for the development of effi-
cient therapeutic strategies for targeting the stromal
microenvironment in breast cancer, especially to prevent
tumor recurrence. However, this goal has been ham-
pered due to paucity of preclinical models that can re-
capitulate breast cancer dormancy and recurrence [11].
Genetically engineered mouse models have provided one
of the few approaches to study the mechanisms respon-
sible for dormancy in vivo in the presence of an intact
immune system and microenvironment. For example,
recent studies performed in a doxycycline-regulatable
erbB2-driven model have helped identify Notch signaling
as important in tumor recurrence [12]. Furthermore, ap-
propriate mouse models are a necessary prerequisite for
testing new targeted therapies directed against the stro-
mal microenvironment as well as the residual dormant
cells. Although distant, as opposed to local, recurrence is
clinically most relevant, studies of dormancy at distant
sites are less tractable. Furthermore, understanding the
mechanisms of local recurrence may help provide in-
sights in developing therapeutic strategies for distant re-
currence. In our studies, we employed a transplantable,
genetically engineered Wnt1/ inducible fibroblast growth
factor receptor 1 (iFGFR1; iR1) mouse mammary tumor
model to study the recurrence of fibroblast growth factor
receptor (FGFR)1-driven breast tumor. The FGFR signal-
ing pathway plays a critical role in regulating normal mam-
mary gland development and tissue homeostasis [13].
Dysregulation of FGFR signaling is associated with tumor
recurrence in lung [14], bladder [13] and pancreatic cancer
[15]. Analysis of copy number abnormalities has shown a
consistently high level of amplification of chromosomal re-
gion 8p11 containing the FGFR1 coding region in early-
stage breast cancers, resulting in overexpression of FGFR1
[13]. While FGFR1 alone resulted in very few palpable tu-
mors with a long latency, FGFR1 is often amplified with
other oncogenes such as c-MYC and CCND1 in breast
cancer, which are downstream targets of the canonical
Wnt signaling pathway [16]. Genetic analyses of mouse
mammary tumor virus integration sites as well as func-
tional studies using transgenic mouse models have pro-
vided considerable evidence supporting the cooperativity
between the FGFR and Wnt pathways in mammary
tumorigenesis [17–20]. Approximately 10 % of breast can-
cers have FGFR1 amplification and its amplification is as-
sociated with early relapse, poor survival and drug
resistance [21]. Taken together, these findings suggest that
FGFR1 is associated with tumor recurrence and targeting
the FGFR1 signaling pathway might prevent tumor relapse.
In this study, treatment of mice bearing Wnt1/iR1 tu-
mors with BGJ398 [22], a potent and selective inhibitor
of the FGFR family of receptor tyrosine kinases, resulted
in an altered collagen-enriched stroma observed both
during tumor dormancy and recurrence. The phosphor-
ylated epidermal growth factor receptor (EGFR) signal-
ing pathway was upregulated in the recurrent tumors,
and the combined inhibition of EGFR and FGFR1 signal-
ing reduced the collagen-enriched stroma and signifi-
cantly delayed tumor recurrence. Overall, these findings
suggest that stroma remodeling during FGFR1 inhibitor
treatment is important both for tumor dormancy and re-
currence, and, furthermore, that recurrence can be de-
layed by inhibiting both FGFR1 and EGFR signaling.
Methods and materials
Kinase inhibitors
The inhibitor NVP-BGJ398 [22] was kindly provided by Dr.
Diana Graus Porta (Novartis Institutes for Biomedical Re-
search, Basel, Switzerland). NVP-BGJ398 was prepared as
10 mmol/L dimethyl sulfoxide (DMSO) stocks. The inhibi-
tor lapatinib (free base) was purchased from LC Laborator-
ies, Woburn, MA (; Cat#: L-4899). Lapatinib was prepared
as 125 mg/ml DMSO stocks. Both inhibitors were diluted
in the corresponding carrier for in vivo experiments.
Animals, tumor transplant, and treatment
MMTV-Wnt1/iR1 mice were generated and character-
ized previously [20]. All mice were FVB background
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littermates. Mice were maintained in accordance with
the NIH Guide for the Care and Use of Experimental Ani-
mals with approval from the Baylor College of Medicine
Institutional Animal Care and Use Committee. Mice were
injected intraperitoneally with 1 mg/kg B/B homodimeri-
zer, a chemical dimerizer for the iFGFR model (Clontech,
Mountain View, CA, every 3 days. Tumors were collected,
dissected into small pieces and transplanted into the
cleared fourth mammary fat pad of 3- to 4-week-old Fvb
mice (Harlan Laboratories, Houston, TX. Following
orthotopic transplantation, the B/B homodimerizer
was injected 1 × 2 weeks after surgery to stimulate
tumor growth. Tumors were measured and volume
was calculated using the following formula: volume =
height × ((diameter/2)2 × π).
Mice were randomly distributed into groups when tu-
mors reached 300–600 mm3. Different groups were treated
for the indicated times with different doses depending upon
the experiment: vehicle (DMSO/D5W/PEG400 (1:2:2)),
NVP-BGJ398 (per oral (p.o.), once daily, 30 mg/kg)), lapati-
nib (p.o., once daily, 150 mg/kg), and the combination of
NVP-BGJ398 and lapatinib. Mice were sacrificed for re-
sidual tissue collection or left for future tumor recurrence.
Immunohistochemistry, immunofluorescence, and
quantification
All sections were pretreated using a sodium citrate anti-
gen retrieval protocol as previously described [23]. Anti-
bodies were used according to the manufacturer’s
protocols (Additional file 1: Table S1).
Quantification of bromodeoxyuridine (BrdU), Ki67,
cleaved caspase 3 (cc3) and S100A8 was obtained by
counting at least three random sections. Positive staining
was then quantified for each picture as a percentage of
the total area of all blue 4′, 6-diamidino-2-phenylindole
(DAPI) nuclear staining. At least a hundred cells per pic-
ture were counted using ImageJ software [24]. The per-
centage of vasculature was quantified using ImageJ
software by analyzing the percentage area of positive
vasculature in the total area [24] with at least five inde-
pendent pictures for each group. All images showed in
the manuscript are representative of at least three mice
and at least three sections for each mouse analyzed.
Masson’s trichrome staining
Tissue sections were deparaffinized, rehydrated with graded
alcohols, fixed with Bouin’s solution (Sigma-Aldrich, The
Woodlands, TX) overnight, washed in running tap water
for 5 min and rinsed with distilled water. Thereafter, the
sections were stained with Weigert Hematoxylin (Sigma-
Aldrich, The Woodlands, TX) for 10 min and washed with
distilled water for cell nuclei staining. Smooth muscle was
stained red with Biebrich Scarlet-Acid-Fuschin (Sigma-Al-
drich, The Woodlands, TX) for 10 min, followed by
immersion in phosphomolybdic phosphotungstic acid
(Sigma-Aldrich, The Woodlands, TX) for 15 min. Collagen
was stained blue with Aniline Blue (Sigma-Aldrich) for
10 min and immersed in 1 % acetic acid for 5 min. Finally,
the tissues were rehydrated with graded ethanol and xylene,
and mounted with mounting medium. The percentage of
collagen was quantified by ImageJ by analyzing the percent-
age area of positive collagen in the total area [24] with five
independent pictures for each group.
Immunoblot analysis and quantification
Pulverized, frozen tissues were resuspended in radioim-
munoprecipitation assay buffer or tissue protein extrac-
tion buffer (T-PER; Life Technologies, Grand Island, NY,
USA) plus phosphatase (Cell Signaling, Denvers, MA)
and protease (Roche, Indianapolis, IN, USA) inhibitors.
Tissue lysates were quantified using the bicinchoninic
acid method (BCA; Pierce, Rockford, IL, USA), separated
using SDS-PAGE, and transferred to PVDF membranes.
All antibodies were used according to manufacturer’s
protocols (Additional file 1: Table S1).
Quantitative reverse transcription PCR
cDNA templates were generated using a High-Capacity
RNA-to-cDNA™ Kit and 2 μg RNA per sample according
to the manufacturer’s protocol (Invitrogen, Grand Island,
NY). Quantitative PCRs were run using SYBR Green re-
agent (Applied Biosystems, Foster City, CA, USA) on a Ste-
pOnePlus thermocycler (Applied Biosystems), and fold
changes were calculated using the comparative CT (ΔΔCT)
method and StepOne software v2.0.1 (Applied Biosystems).
Primer sequences for amphiregulin (Areg) are: forward
5′- GCC ATT ATG CAG CTG CTT TGG AGC -3′,
reverse 5′- TGT TTT TCT TGG GCT TAATCA CCT -3′.
Reverse phase protein array analysis
Reverse phase protein array (RPPA) assays were carried
out as described previously with minor modifications [25].
Protein lysates were prepared from tissue samples with
tissue protein extraction reagent (TPER; Pierce) supple-
mented with 450 mM NaCl and a cocktail of protease and
phosphatase inhibitors (Roche Life Science). Protein
lysates at 0.5 mg/ml of total protein were denatured in
SDS sample buffer (Life Technologies) containing 2.5 %
2-mercaptoethanol and treated at 100 °C for 8 min. The
Aushon 2470 Arrayer (Aushon BioSystems, Billerica, MA,
USA) with a 40-pin (185 μm) configuration was used to
spot lysates onto nitrocellulose-coated slides (Grace Bio-
labs, Bend, OR, USA) using an array format of 960 ly-
sates/slide (2880 spots/slide) with each sample spotted as
technical triplicates including test and control lysates.
Antibody labeling was performed at room temperature
with an automated slide stainer Autolink 48 (Dako,
Carpinteria, CA, USA). Slides were prepared for antibody
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labeling by blocking for 1 h with I-Block reagent (Ap-
plied Biosystems) followed by 15 min with Re-Blot re-
agent (Dako). After blocking, slides were loaded to
the autostainer.
Each slide was incubated with primary antibody for
30 min followed by an appropriate biotinylated-secondary
antibody for 15 min (goat anti-mouse IgG for mouse
monoclonal primary antibodies, goat anti-rabbit IgG for
rabbit primary antibodies, or rabbit anti-goat IgG for goat
primary antibodies (Vector, Burlingame, CA, USA)). As a
signal amplification step, slides were incubated for 15 min
with Vectastain-ABC Streptavidin-Biotin Complex (Vec-
tor, PK-6100) followed by 15 min with TSA-plus Biotin
Amp Reagent diluted at 1:250 (Perkin Elmer, Waltham,
MA, USA). A fluorescent detection signal was generated
by incubating slides for 15 min with a 1:50 dilution of LI-
COR IRDye 680 Streptavidin (Odyssey, Lincoln, NE,
USA). Total protein content of each spotted lysate was
assessed by fluorescent staining for selected subset of slide
with Sypro Ruby Protein Blot Stain according to the man-
ufacturer’s instructions (Molecular Probes, Eugene, OR,
USA). Fluorescent-labeled slides were scanned on a Gene-
Pix AL4200 scanner, and the images were analyzed with
GenePix Pro 7.0 (Molecular Devices, Sunnyvale, CA).
Total fluorescence signal intensities of each spot were ob-
tained after subtraction of the local background signal for
each slide, and were then normalized for variation in total
protein, background and non-specific labeling using a
group-based normalization method as described [26] with
modification. For each spot on the array, the background-
subtracted foreground signal intensity was subtracted by
the corresponding signal intensity of the negative control
slide (omission of primary antibody) and then normalized
to the corresponding signal intensity of total protein for
that spot. The distribution of the normalized data were
summarized by descriptive statistics (e.g., mean, SD, range,
median and quartiles) and tested for normality (e.g.,
Shapiro-Wilk and Shapiro-Francia test) using R statistical
software. We determined significantly changed proteins
between experimental groups by employing Student’s t-
test (significant for p < 0.05) and requesting a fold change
of at least 1.5 ×.
There are a total of 204 validated antibodies for RPPA.
Of these, 132 antibodies detect total protein and 72 detect
specific phosphorylated states of proteins known to be
markers of protein activation states. Antibody validation
for RRPA includes the selective detection of a single pre-
dominant protein band of the expected size by immuno-
blot assay of multiple known positive and negative tissues
or cell lines and quality performance with the control ly-
sates by RPPA assay. Each primary antibody is used at a
pre-determined optimal dilution that generates appropri-
ate differential signals across the range of control lysates.
The validated antibodies represent proteins in various
signaling pathways and cell functional groups includ-
ing growth factor receptors, cell cycle, cell prolifera-
tion, apoptosis, EMT, stem cells, DNA damage, cell
stress, autophagy, cytokines, protein translation and
gene transcriptional activators and repressors. For a




The WNT signature is derived from “Additional file 5”
in Huang et al. [27]. For each tumor sample, a WNT sig-
nature score is calculated as the sum of upregulated
genes subtracted by the sum of downregulated genes.
The score is then re-scaled linearly to [0, 1]. Tumors
with FGFR genome copy number ≥4 and/or gene ex-
pression value ≥mean (all samples) + SD (all samples)
are defined as FGFR-amplified tumors. Survival analyses
are performed using the survdiff function of the survival
package in the R statistical software.
Statistical analysis
The significance of fold changes for immunofluorescence/
immunohistochemistry and reverse transcription PCR re-
sults was determined using student’s t tests and analysis of
variance tests. All tests and graphical representation of
data were performed using GraphPad Prism. For latency
calculation, days were counted from the day when the
treatment stopped to the day when recurrent tumors
reach 100 mm3. Survival analysis was used to compare
time to major tumor regression (defined as <20 % of base-
line) and time to relapse (defined as regrowth >20 % of
baseline, around 100 mm3). The generalized Wilcoxon
test was used to test for differences. Shaded regions on the
graphs show 95 % confidence regions.
Consent statement
We confirm that this study did not involve human pa-
tients and no consent was required.
Results
Inhibiting FGFR1 leads to rapid regression of Wnt1/iR1
tumors
Previously, MMTV-Wnt1/iR1 mice were shown to de-
velop tumors significantly faster than MMTV-Wnt1
alone. Additionally, the average tumor multiplicity was
significantly greater in the Wnt1/iR1 bigenic mice com-
pared to Wnt1 alone, and Wnt1/iR1 tumors grew signifi-
cantly faster than the Wnt1 tumors [20]. Interestingly,
it has been reported that in the iR1 model, activation
of FGFR1 alone only resulted in increased lateral bud-
ding, alveolar hyperplasia, as well as increased macro-
phage recruitment to hyperplastic lesions, but very
few palpable tumors developed in virgin mice even after
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very long latencies [28, 29]. The importance of coopera-
tive effects between Wnt and FGFR1 signaling observed
in mouse mammary tumor models is supported by our
recent analysis of patient outcomes in human breast
cancer. While either active WNT signaling or FGFR1
amplification/overexpression is associated with poor
disease-specific survival (Fig. 1a and b), tumors with both
pathways activated exhibited the worst prognosis, sup-
porting that the two pathways may cooperate to drive
tumor progression in human breast cancer (Fig. 1c).
The bigenic MMTV-Wnt1/iR1 mammary tumor model
has multiple advantages, such as an intact microenviron-
ment, reproducible tumor kinetics and a consistent genetic
background. Thus, we transplanted the tumor tissues from
Wnt1/iR1 spontaneous tumors to the cleared fat pads of
syngeneic FvB mice. Transplanted Wnt1/iR1 tumors main-
tained a similar histology as compared to spontaneous tu-
mors (Fig. 2a). Tumors were stained for the luminal marker
Keratin 8 (K8) and the basal marker Keratin 5 (K5). Trans-
planted Wnt1/iR1 tumors displayed a large expansion of
the luminal compartment, which is consistent with the
Wnt1/iR1 spontaneous tumors (Fig. 2a). Additionally, the
vasculature appears similar in the transplanted as compared
to the spontaneous tumors (Fig. 2b). Since the Wnt1/iR1
tumor cells express an epitope HA tagged iFGFR transgene,
immunofluorescence staining for K8, K5 and the HA tag
also were performed to verify if the tumors were derived
from the original transplants (Fig. 2c). The overlapping ex-
pression of K8 and HA, but not K5 and HA, was observed
in the transplanted tumors, as seen previously in spontan-
eous tumors [20]. These results indicate that the trans-
planted Wnt1/iR1 tumors maintained characteristics
similar to spontaneous Wnt1/iR1 tumors, and can be
used as a preclinical FGFR1-driven mouse mammary
tumor model.
NVP-BGJ398 (BGJ398) is a potent and selective inhibi-
tor of the FGFR family of receptor tyrosine kinases [22].
To assess the effect of BGJ398 on Wnt1/iR1 tumors, the
Wnt1/iR1 transplanted tumors were consecutively
treated with this inhibitor for 10 days (Fig. 2d) resulting
in rapid tumor regression (Fig. 2e). Immunofluorescence
staining of S phase proliferation marker BrdU, prolifera-
tion marker Ki67, and apoptotic marker cc3 showed a
dramatic decrease in both cell proliferation and an
Fig. 1 Human breast tumors with both FGFR1 amplification/overexpression and active WNT signaling exhibited the worst prognosis. a Kaplan-Meier
curves show the disease-specific survival of patients in METABRIC dataset stratified by the statuses of WNT signature. WNT status is determined by
ranking the continuous WNT score (sum of upregulated genes – sum of downregulated genes), and then separating all patients into three equal
tertiles. b. The Kaplan-Meier curves show the disease-specific survival of patients in METABRIC dataset stratified by the status of FGFR1 amplification/
overexpression. c. Kaplan-Meier curves show the disease-specific survival of patients in METABRIC dataset stratified by the status of FGFR1
amplification/overexpression and WNT signature. The number of events and total patients in each subset is indicated in parentheses. The p values are
calculated based on log rank tests. FGFR1 Fibroblast growth factor receptor 1
Holdman et al. Breast Cancer Research  (2015) 17:141 Page 5 of 17
increase in cell apoptosis 48 hours after BGJ398 treatment
(Fig. 2f and g). In particular, increased apoptosis occurred
mostly within the luminal cells, resulting in the shrinkage
of the expanded luminal compartment (Additional file 2:
Figure S1A). According to the earlier observations that
FGFR1 signaling enhanced protein translation pathways
[20], we performed immunoblot assay on cell lysates from
the control and BGJ398-treated tumors. The results
showed that the translation pathway components, p-
mTOR and p-4EBP1, were markedly inhibited 24 hours
Fig. 2 Transplanted Wnt1/iR1 tumors rapidly regress after inhibiting FGFR1 signaling following treatment with BGJ398. a Histological analysis of
transplanted Wnt1/iR1 tumors as compared to spontaneous tumors. Upper panel: Hematoxylin and eosin (H&E) stain of spontaneous and
transplanted Wnt1/iR1 tumors. Lower panel: Immunofluorescence double staining of luminal K8 (green) and basal K5 markers (red) in spontaneous
and transplanted Wnt1/iR1 tumor sections. Nuclear staining is shown in blue (DAPI). b Immunofluorescence staining and quantification for
vasculature using anti-CD31 in spontaneous and transplanted Wnt1/iR1 tumors; p = 0.51. c Immunofluorescence double staining for basal K5
(green) and HA epitope (red), and luminal K8 (green) and HA epitope (red) in spontaneous and transplanted Wnt1/iR1 tumor sections. Nuclear
staining is shown in blue (DAPI) in all panels. d BGJ398 treatment scheme. e Tumor regression curve after receiving BGJ398 treatment, compared
to control group treated with vehicle. Eleven mice in BGJ398 treatment group, four mice in vehicle treatment control group, 15 mice in total. f
Immunofluorescence staining of the S phase proliferation marker BrdU, proliferative marker Ki67 and apoptotic marker cc3 in tumors from control
and treatment groups (48 hours after BGJ398 treatment). g Quantification of immunofluorescence staining of nuclear BrdU, Ki67 and cc3 in tumor
sections. BrdU (n ≥ 7): ****p < 0.0001; Ki67 (n ≥ 4): **p < 0.005; cc3 (n ≥ 6): **p < 0.005. Comparisons represent control versus 48 hours after BGJ398
treatment. Values are shown as mean ± SEM. BrdU Bromodeoxyuridine, cc3 Cleaved caspase 3, DAPI 4′, 6-Diamidino-2-phenylindole
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after BGJ398 treatment (Additional file 2: Figure S1B).
RPPA results further showed that key components of pro-
tein translation pathways, such as p70S6K, p-p70S6K, p-
mTOR, and p-4E-BP1, were inhibited 6 and 24 hours after
treatment (Additional file 3: Figure S1C). Downregulation
of components of the MAPK pathway, a major down-
stream pathway of FGFR1, was also observed, such as p-
MEK1, c-Fos, and p-c-Fos (Additional file 2: Figure S1C).
Taken together, these results confirmed that the
transplanted tumor model exhibited a similar histo-
logical pattern to the spontaneous Wnt1/iR1 tumors.
The transplanted tumors robustly responded to BGJ398
treatment, leading to a rapid regression as a result of the in-
hibition of both proliferation and an increase in apoptosis.
After cessation of treatment, fully regressed Wnt/iR1
tumors recur spontaneously following a period of
dormancy
Downregulation of FGFR1 signaling in the established
Wnt1/iR1 mammary tumors resulted in rapid regression
to a nonpalpable state. However, all mice developed spon-
taneous tumor recurrences ranging from 1 to 4 months
following the cessation of treatment (Fig. 3a and b). Re-
gardless of the initial tumor size prior to treatment, tu-
mors showed similar kinetics of regression as well as
recurrence (Additional file 3: Figure S2A–C). Injection of
dimerizer during the course of dormancy had no ef-
fect on promoting tumor recurrence (Additional file
3: Figure S2G and H). Furthermore, when BGJ398
treatment was extended from 10 days to 20 days, no
significant difference in the latency of tumor recurrence
was observed (Additional file 3: Figure S2D and E). In
addition, no differences in change of body weight were de-
tected in both treatment groups (Additional file 3: Figure
S2F). However, three out of eight mice died during the ex-
tended 20-day treatment (0/5 dead in the control group).
These data suggest that sustained BGJ398 treatment did
not affect the kinetics of tumor regression or recurrence,
and because of apparent toxicity was not warranted. To-
gether, these results suggest that 10-day BGJ398 treatment
is sufficient to kill the majority of tumor cells without re-
ducing body weight, leaving a nonpalpable mass of malig-
nant cells.
Most of the primary recurrent tumors (13 out of 16
mice) were still sensitive to treatment with BGJ398, but
recurred when treatment was stopped (Fig. 3c and d).
Interestingly, the second recurrence occurred with shorter
latency (7.8 ± 1.4 days vs. 38.7 ± 11.0 days) (Fig. 3e). Half
of the secondary recurrent tumors (three out of six mice)
still responded to BGJ398 treatment but recurrence again
occurred (Additional file 4: Figure S3A and B). The la-
tency for the third recurrence was much shorter than the
first and second recurrences (22.3 ± 8.7 days vs. 6.7 ±
3.1 days vs. 3.8 ± 1.8 days) (Additional file 4: Figure S3C).
In addition, 18 % (3 out of 16) of primary recurrent
tumors and 50 % (three out of six) secondary recur-
rent tumors eventually developed treatment resistance
(Additional file 5: Figure S4A). To test if the recur-
rent tumors were derived from the primary tumors,
immunofluorescence co-staining was performed for
either the luminal marker K8 and the HA epitope or
the basal marker K5 and the HA epitope (Additional
file 6: Figure S5C and D). The recurrent tumors ex-
clusively co-expressed K8 with the HA tag, indicating
that these tumor cells were derived from the original
transplanted Wnt1/iR1 tumor. Although the recurrent
tumors still displayed extensive luminal compartments
similar to the primary tumors, these luminal cells
were more disorganized and expanded (Fig. 3f ). In
addition, the basal cell layer was further disrupted
and often lost in the second recurrence (Fig. 3f ).
Moreover, immunofluorescence analysis revealed an
increased expression of Ki67-positive cells as com-
pared to the primary tumors (Additional file 6: Figure
S5A and B). In summary, these data revealed that
most recurrent tumors were still sensitive to BGJ398
treatment. However, they were not eliminated and
subsequent recurrences appeared with altered hist-
ology, accompanied by a further loss of luminal
organization, a loss of organization of the basal layer,
and an increase in proliferating cells. This suggests
that targeting FGFR1 alone was not sufficient to
eradicate the residual Wnt1/iFGFR1 tumor cells.
Residual tumor cells are surrounded by extensive stroma
exhibiting a fibrotic response after BGJ398 treatment
Next, we analyzed the residual tumor cells in the fat
pads after BGJ398 treatment. At the end of 10-day treat-
ment, the tumors were no longer palpable (Fig. 4a).
Hematoxylin and eosin staining staining showed that a
few epithelial cells in the fat pads were left after the
treatment, surrounded by a large amount of fibrous tis-
sue (Fig. 4b). Trichrome staining showed that the dense
stroma was enriched in collagen (Fig. 4b and c). How-
ever, expression of the proliferation marker Ki67 was not
detected in the residual epithelial cells nor was the apop-
tosis marker cc3 (Fig. 4d and e), suggesting a state of
dormancy [30]. Interestingly, double immunofluores-
cence staining for K8 and K5 shows that the dormant
cells were organized into what appeared to be a normal
mammary gland structure, with a basal cell layer and a
luminal compartment (Fig. 4f ).
To characterize the stroma around residual tumor
cells, immunofluorescence staining was performed using
antibodies against alpha smooth muscle actin (α-SMA+;
myoepithelial cell marker), tenascin-C (tumor stromal
marker), and also CD31 as a vasculature marker (Fig. 4g).
In a comparison of MMTV-Wnt1 to bigenic MMTV-
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Wnt1/iFGFR1 tumors we observed a marked increase in
anti-S100A8 staining (Additional file 7: Figure S6A), which
could represent either neutrophils or myeloid-derived
suppressor cells (MDSCs). Further characterization re-
vealed a positive correlation of S100A8 staining with
MDSCs by FACS analysis using anti-CD11b and anti-GR1
antibodies (Additional file 7: Figure S6B) as well as anti-
Ly6G (data not shown). Residual tissue after 10 days treat-
ment exhibited a more organized and continuous α-SMA+
cell layer which encapsulated the residual epithelial cells,
Fig. 3 Fully regressed Wnt1/iR1 tumors after BGJ398 treatment recur slowly following cessation of treatment. a Scheme for BGJ398 treatment and tumor
recurrence (first recurrence, n= 16). b Timing of tumor regression and recurrence for individual Wnt1/iR1 tumors. BGJ398 treatment was started on day 0,
and stopped on day 10. c Scheme for BGJ398 treatment and tumor recurrence (second recurrence, n= 7). d Timing of tumor regression, first and second
recurrence for individual Wnt1/iR1 tumors. e Comparison of the recurrent latency between the first and the second recurrence. Latency is calculated
from the day of BGJ398 withdrawal to the day when the recurrent tumor reached 100 mm3; p< 0.05. f Immunofluorescence double staining of K5 (red)
and K8 (green) in primary tumors and recurrent tumors. Nuclear staining is shown in blue (4′, 6-diamidino-2-phenylindole (DAPI)) in all panels
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in contrast to the untreated tumors which had a disrupted
and sparse α-SMA+ layer (Fig. 4g). Moreover, there was
increased expression of tenascin-C in the stroma. In
addition, the vasculature was disrupted and infiltrating
MDSCs were absent in the residual tissue after BGJ398
treatment (Fig. 4g–i). These findings suggest that BGJ398
treatment resulted in disrupted vasculature and markedly
decreased tumor-infiltrating MDSCs. At the same time
following treatment there was an increased expression of
tenascin-C in the stroma, and the α-SMA+ myoepithelial
cell layers were reconstituted around the dormant epithe-
lial tumor cells, which displayed a normal mammary gland
basal-luminal structure.
Recurrent tumors contain the collagen-enriched stroma
with upregulation of tenascin-C and phosphorylated EGFR
expression
To investigate whether the stroma is enriched in the re-
current tumors, we collected the recurrent tumors and
performed histological analysis. The recurrent tumors
showed increased fibrosis similar to the stroma from the
residual tissue (Fig. 5a). Trichrome staining further dem-
onstrated that the stroma was also enriched in collagen
(Fig. 5a and b). Immunofluorescence staining showed el-
evated expression of tenascin-C in the stroma as com-
pared to the primary tumors (Fig. 5c). S100A8 staining
also suggested that there was an increase in the number
of MDSCs in the recurrent as compared to the primary
tumors (Fig. 5c and d). However, no difference was de-
tected in the expression pattern of α-SMA+ between re-
current and primary tumors (Fig. 5c). RPPA performed
to investigate the possible molecular mechanisms in-
volved in tumor recurrence indicated that the recurrent
tumors had elevated phosphorylated EGFR (p-EGFR) ex-
pression (Fig. 5e). The upregulation of p-EGFR was also
observed in the recurrent tumors by immunoblot assay
(Additional file 8: Figure S7D). An increase of Areg, one
of the principal EGFR ligands expressed in the develop-
ing mammary gland, was also detected in the recurrent
as compared to the primary tumors (Fig. 5f and g). To-
gether, these data revealed dense collagen fibrosis, in-
creased expression of tenascin-C, increased infiltration
of MDSCs in the stroma of the recurrent tumors, and
upregulation of p-EGFR signaling as well as its ligand
Areg in the recurrent tumors.
Combinatorial blocking of EGFR and FGFR signaling
significantly delays tumor recurrence, along with the loss
of stroma in recurrent tumors
To test if the EGFR pathway is necessary for recurrence,
we utilized an EGFR inhibitor, lapatinib, to inhibit EGFR
pathways in vivo. Although lapatinib also inhibits ErbB2,
our RPPA results revealed no evidence for ErbB2 signal-
ing in the primary and recurrent tumors (data not
shown). Moreover, p-ErbB2 expression was not detect-
able in primary or recurrent tumors in this mouse model
(Additional file 8: Figure S7D). The results also showed
that lapatinib successfully inhibited p-EGFR expression
(Additional file 8: Figure S7E). Mice treated with lapati-
nib alone showed no tumor regression as compared to
control mice. Mice treated with BGJ398 plus lapatinib
showed the same kinetics of tumor regression as com-
pared to the BGJ398 group alone (Fig. 6a; Additional file
9: Figure S8). However, mice treated with both BGJ398
and lapatinib exhibited delayed tumor recurrence as
compared to mice treated with single treatment of
BGJ398 (Fig. 6b; Additional file 9: Figure S8). In order to
investigate the mechanism that led to the delayed recur-
rence, we collected the residual tissue after treatment as
well as recurrent tumors from both groups and per-
formed histological analysis. We found that the residual
tissue after combinatorial treatment showed less stroma
but more adipocytes (Fig. 6c and d). The residual tumor
cells in both treatment groups were organized into a
normal mammary gland structure, with a basal cell layer
and a luminal compartment (Fig. 6e). The recurrent tu-
mors from the combinatorial treatment exhibited re-
duced stroma and collagen expression similar to that
(See figure on previous page.)
Fig. 4 Residual tumor cells are surrounded by extensive stroma exhibiting a fibrotic response after BGJ398 treatment. a Mammary glands after 10-day
BGJ398 treatment as compared to controls. b Histological analysis of tumors in BGJ398 treatment groups (10 days of treatment) as compared to
control group treated with vehicle. Upper panel: Hematoxylin and eosin (H&E) staining. Lower panel: Trichrome staining. c Quantification of percentage
of collagen in tumors. **p < 0.005, comparisons represent control versus 10 days after BGJ398 treatment. Values are shown as mean ± SEM. d
Immunofluorescence double staining of proliferation marker Ki67 (green) in HA (red)-positive tumor cells and apoptosis marker cc3 (red) in tumor cells
after 10 days BGJ398 treatment as compared to control group treated with vehicle. e Quantification of Ki67-positive cells in HA-positive cells after
10 days BGJ398 treatment as compared to a control group treated with vehicle alone, ****p < 0.0001; quantification of cc3-positive cells after 10 days
BGJ398 treatment as compared to control group treated with vehicle alone, ***p = 0.0009. f Immunofluorescence double staining of K5 and K8 in
tumors treated with BGJ398 for 10 days as compared to tumors in control group treated with vehicle. Upper row: K8 (green) and K5 (red), magnification
200×. Lower row: K8 (red) and K5 (green), magnification 400×. g Immunofluorescence staining of α-SMA, tenascin-C, CD31 and S100A8 in tumors
treated with BGJ398 for 10 days as compared to tumors in control group treated with vehicle. h Quantification of vasculature after 10 days BGJ398
treatment as compared to control group treated with vehicle alone, ****p < 0.0001. i Quantification of S100A8-positive cells after 10 days BGJ398
treatment as compared to control group treated with vehicle alone, **p = 0.0012. α-SMA alpha smooth muscle actin, cc3 Cleaved caspase 3, DAPI
4′, 6-Diamidino-2-phenylindole
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observed in the primary tumors (Fig. 6f and g). Unlike
recurrent tumors in the BGJ398 treatment group, recur-
rent tumors from the combined treatment group showed
organized expanded luminal cells surrounded by a de-
fined basal cell layer (Fig. 6h). There were fewer prolifer-
ating cells in the recurrent tumors after the combined
treatment (Fig. 6i and j). Interestingly, in contrast to the
recurrent tumors that arose following the single treat-
ment of BGJ398, which exhibited a large number of
MDSCs, only a few MDSCs were observed in the recur-
rent tumors from the combined treatment group
(Fig. 6k). In addition, increasing numbers of α-SMA+
myoepithelial cells were found in the recurrent tumors
from the combined treatment group, and these myoe-
pithelial cells formed continuous layers around the
tumor epithelial cells (Fig. 6l). In addition, tumors
treated with lapatinib for only 8 days contained reduced
stroma as compared to tumors in the control group
(Additional file 8: Figure S7A–C).
In summary, these results show that blocking both the
FGFR1 and EGFR signaling pathways significantly delays
tumor recurrence. Recurrent tumors from the combined
treatment contained reduced stroma and MDSCs, and
exhibited an increased myoepithelial cell organization.
Discussion
In this study, a transplantable mouse model for Wnt1/
iFGFR1-driven breast cancer was employed to demon-
strate changes in the stromal microenvironment and
EGFR signaling occurring during tumor dormancy and re-
currence. Targeting FGFR1 alone resulted in rapid tumor
regression, but tumors eventually recurred with latencies
of 1 to 4 months. The tumors recurred from dormant re-
sidual cells surrounded by a large amount of collagen-
enriched stroma. In addition, upregulation of tenascin-C
and p-EGFR was observed in the recurrent tumors and
inhibiting p-EGFR signaling significantly delayed recur-
rence without affecting initial tumor regression. These re-
sults provide insights in developing new strategies for
cancer treatment.
Upon treatment with BGJ398, Wnt1/iR1 tumor cells
stopped proliferating. A large number of cells immedi-
ately underwent apoptosis, and tumors shrank to a non-
palpable size within 5 days. This fits the oncogene
addiction paradigm, which dictates that the survival of a
cancer cell becomes unusually dependent on the activity
of a single gene product [31]. Therefore, FGFR signaling
might be a potentially promising therapeutic target in
cancers exhibiting FGFR1 overexpression. However, tu-
mors recurred after cessation of the BGJ398 treatment.
Residual tumor cells remaining after treatment with
BGJ398 led to subsequent recurrence. Moreover, although
the initial recurrence was usually BGJ398-sensitive after
several cycles of treatment, some of the recurrent tumors
became invasive and developed resistance to BGJ398
treatment (Additional file 5: Figure S4).
In the present study, the residual dormant cells were
surrounded by a collagen-enriched fibrotic stroma with
upregulation of tenascin-C. The vasculature was dis-
rupted, and tumor-infiltrating MDSCs were diminished at
the end of the treatment. Increased α-SMA+ cells were ob-
served around the residual epithelial cells. In the mam-
mary gland, α-SMA+ myoepithelial cells act as a natural
barrier and reside between the epithelial cells and the sur-
rounding stroma. Molecules from the stroma must pass
through the myoepithelial cell layer to reach the epithelial
cells surrounding the lumen, and vice versa. Disruption of
this structure causes alterations in microenvironment and
is a prerequisite for ductal carcinoma in situ progression
and breast tumor invasion [32]. These changes may
have inhibited the ability of BGJ398 to target the re-
sidual cancer cells, thus rendering the residual cells
resistant to the treatment. Another possibility is that
BGJ398 treatment selected for a resistant subpopula-
tion within the tumor—namely, the tumor-initiating
cells, or “cancer stem cells (CSCs)”. The tumor dor-
mancy and CSC theories have many similarities. For
example, the dormancy theory suggests that there is a
small subpopulation of dormant cells responsible for
resistance and tumor recurrence. Likewise, the CSC
hypothesis similarly predicts that a subset of self-
renewing cancer cells is responsible for tumor initi-
ation, therapy resistance, delayed cancer recurrence
and metastatic progression. In addition, several bio-
logical mechanisms, such as cell cycle modifications,
alteration of angiogenic processes, and modulation of
antitumor immune responses, involved in controlling
the dormant state of a tumor, may also be observed
(See figure on previous page.)
Fig. 5 Collagen-enriched stroma in the recurrent tumors with increased tenascin-C and p-EGFR expression. a Hematoxylin and eosin (H&E) and
trichrome staining of primary and recurrent tumors. b Quantification of percentage of collagen in primary, first recurrent, and second recurrent
tumors. *p < 0.05, ***p < 0.001, comparisons represent primary versus first recurrence versus second recurrence. Values are shown as mean ± SEM.
c Immunofluorescence staining of α-SMA, tenascin-C and S100A8 in primary and recurrent tumors. Nuclear staining is shown in blue (DAPI; and
subsequent panels). d Quantification of S100A8+ MDSCs in recurrent tumors (n ≥ 5). **p < 0.005, comparisons represent primary versus first
recurrence versus second recurrence. Values are shown as mean ± SEM. e p-EGFR expression levels in recurrent Wnt1/iR1 tumors through RPPA
analysis. f Quantitative RT-PCR analysis of Areg normalized to GAPDH (n = 3). **p < 0.005. Values are shown as mean ± SEM. g Immunofluorescence
staining of Areg in primary and recurrent tumors. Areg Amphiregulin, α-SMA alpha smooth muscle actin, DAPI 4′, 6-Diamidino-2-phenylindole,
FGFR1 Fibroblast growth factor receptor 1, p-EGFR Phosphorylated epidermal growth factor receptor
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in CSCs. In fact, quiescence and immune escape are
emerging hallmark features of at least some CSCs,
suggesting that there is a significant overlap between
dormant cancer populations and CSCs [33]. Unfortu-
nately, with the current transplanted tumor model it
was not feasible to isolate the small number of re-
sidual cells to directly test these hypotheses and a
specific biomarker for FGFR signaling is not available.
Future studies using a fluorescently and biolumines-
cently tagged model may help facilitate these studies.
The increasing collagen-enriched stroma observed in
the residual tissue was also found in the recurrent
tumors. Other studies have shown that fibrotic foci with
dense collagen are often observed in primary tumors of
breast cancer patients with lymph node metastases at
high risk of recurrence [34, 35]. Recent evidence also
shows that breast cancer cells in a dense collagen stro-
mal environment are invasive, but dormant. These cells
encapsulated in collagen can resist local and adjuvant
therapies, leading to local recurrence [36]. A high level
of procollagen type I, a marker for collagen synthesis,
has been detected in the serum of patients with recur-
rent breast cancer [37]. A type I collagen-enriched fi-
brotic environment has been shown to be able to switch
(See figure on previous page.)
Fig. 6 Inhibition of both EGFR and FGFR signaling significantly delays tumor recurrence. a Survival analysis of tumor regression after single
BGJ398 treatment or combined BGJ398 and lapatinib treatment. Six mice in the single BGJ398 treatment group, eight mice in the combined
BGJ398 and lapatinib treatment group, 14 mice in total; p = 0.5271. b Survival analysis of tumor recurrence after single BGJ398 treatment or
combined BGJ398 and lapatinib treatment. Six mice in the single BGJ398 treatment group, eight mice in the combined BGJ398 and lapatinib
treatment group, 14 mice in total; p = 0.0005. c Histological analysis of tumors treated with BGJ398 alone or combined BGJ398 and lapatnib for
10 days. Upper panel: Hematoxylin and eosin (H&E) staining. Lower panel: trichrome staining. d Quantification of percentage of collagen in tumors
treated with BGJ398 alone or combined BGJ398 and lapatnib for 10 days; p = 0.0079. e Immunofluorescence double staining of K5 (green) and K8
(red) in tumors treated with BGJ398 alone or combined BGJ398 and lapatnib for 10 days. Nuclear staining is shown in blue (DAPI). f Histological
analysis of primary tumors and tumors after single treatment or combined treatment. Upper panel: H&E staining. Lower panel: trichrome staining.
g Quantification of percentage of collagen in primary tumors, recurrent tumors from BGJ398 treatment, and recurrent tumors from BGJ398 and
lapatinib treatment; ****p < 0.0001. Values are shown as mean ± SEM. h. Immunofluorescence double staining of K5 (red) and K8 (green) in primary
tumors and tumors after single treatment or combined treatment. Nuclear staining is shown in blue (DAPI; and subsequent panels). i Immunofluorescence
staining of BrdU in primary tumors and tumors after single treatment or combined treatment. j Quantification of BrdU-positive cells in recurrent tumors
from combined treatment group (n= 5); ****p< 0.0001. Values are shown as mean ± SEM. k Immunofluorescence staining and quantification of S100A8
(red) in tumors after single treatment or combined treatment; p= 0.0084. l Immunofluorescence staining of α-SMA (red) in tumors after single treatment or
combined treatment. α-SMA alpha smooth muscle actin, BGJ BGJ398, BrdU Bromodeoxyuridine, DAPI 4′, 6-Diamidino-2-phenylindole, Lap Lapatinib,
Recur Recurrence
Fig. 7 Model of mechanism of tumor recurrence after BGJ398 treatment. Before the treatment with the FGFR inhibitor, BGJ398, Wnt1/iR1 tumor cells
are surrounded by α-SMA+ myoepithelial cells and stroma, which is comprised of stromal fibroblasts, MDSCs, blood vessels and collagen. Upon BGJ398
treatment, the majority of the tumor cells die, leaving a nonpalpable mass of tumor cells with remodeled stroma, including thickened myoepithelial cell
layers, increased collagen, and upregulation of tenascin-C. Vasculature and MDSCs are eliminated after BGJ398 treatment. Over time, EGFR signaling is
upregulated, accompanied by remodeled stroma and tumor recurrence. The stroma in the recurrent tumors maintains elevated tenascin-C
and increased collagen expression. However, the recurrent tumors have a disrupted myoepithelial cell layer and increased MDSC infiltration indicating
that they may be more invasive as compared to the primary tumors. iR1 Inducible fibroblast growth factor receptor 1, MDSC Myeloid-derived tumor
suppressor cell, p-EGFR Phosphorylated epidermal growth factor receptor
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dormancy to proliferation and induce metastatic growth
from these tumor cells [38]. More interestingly, we found
that recurrent tumors show a loss of basal cell layers,
resulting in direct contact between luminal cells and stro-
mal cells. One of the key characteristics of invasive cancer
progression is the loss of myoepithelial cell layer and base-
ment membrane, since normal myoepithelial cells form a
natural barrier against cancer cell invasion [39]. MDSCs
are a heterogeneous population of immature myeloid cells,
which may inhibit the immunosuppressive activity of T
cells. The level of MDSCs also is correlated with disease
burden and is a potential prognostic marker for breast
cancer [40]. Our data revealed increased MDSC infiltra-
tion in the recurrent tumors, indicating that the recurrent
tumor cells could be potentially invasive and metastatic,
an observation that warrants further study.
Tenascin-C, an extracellular matrix glycoprotein, is re-
quired for the active remodeling process of tissues, such
as wound healing and inflammation [41]. Increased ex-
pression of tenascin-C has been also found in the stroma
of various cancers and its expression is predictive of
local recurrence, metastatic dissemination of cancer cells
and anti-cancer treatment responsiveness in breast can-
cer [41]. Our results show that tenascin-C is upregulated
upon the BGJ398 treatment, and high expression of
tenascin-C is maintained during dormancy and recur-
rence. Because tenascin-C has EGF-like repeats which
bind to EGFR with low affinity, it has been suggested to
be an EGFR ligand originating from the extracellular
matrix [42]. These data suggest that overexpression of
tenascin-C in the recurrent tumors could lead to the ac-
tivation of EGFR signaling. The RPPA data consistently
showed upregulated p-EGFR in the recurrent tumors.
Areg is another important EGFR ligand, especially in
mammary gland development, and expression of Areg
was increased in the recurrent tumors. EGFR signaling
in the stroma is thought to be mediated by Areg in the
developing mammary gland [43]. Previous studies using
the iFGFR model have shown that Areg expression can
be induced by FGFR1 and leads to activation of EGFR
signaling to promote mammary tumorigenesis [44]. This
and other studies suggest the existence of crosstalk be-
tween EGFR and FGFR signaling during mammary
tumorigenesis. In vitro and in vivo data showed that com-
binatorial inhibition of the EGFR and FGFR signaling
pathways in various human cancers results in better out-
comes as compared to the single regimens alone [45, 46].
The current study, for the first time, showed that blocking
EGFR signaling significantly delayed the recurrence of
BGJ398-treated mammary tumors. Together, these find-
ings suggest that the activation of EGFR signaling is corre-
lated with stroma remodeling in tumor recurrence
(Fig. 7), and that inhibition of EGFR signaling may help
delay recurrence.
Although inhibiting both FGFR1 and EGFR resulted in
delayed recurrence, no difference was observed in initial
tumor regression as compared to inhibiting FGFR1
alone. This observation suggests that pathological
complete response, defined as the absence of invasive
cancer in breast and lymph nodes, following chemother-
apy may not be the best index of neoadjuvant efficacy.
Some chemotherapy regimes might have different dis-
ease outcomes, although they result in the same patho-
logical complete response rates as compared to other
regimes [47, 48]. Our results also provide additional sup-
port for the role of the stromal microenvironment in
tumor dormancy and recurrence. In addition, the im-
portance of EGFR signaling in tumor dormancy and re-
currence of FGFR1-driven mammary tumors provides a
further rationale for combinatorial treatments in breast
cancers harboring FGFR1 amplification.
Conclusion
Although breast cancer patient survival has been im-
proved through early detection and adjuvant targeted
therapies, many patients, though exhibiting no detectable
minimal residual disease in some cases for many years,
suffer relapse and tumor recurrence. Understanding the
mechanisms involved in dormancy and tumor recurrence
is important for developing new therapeutic strategies for
cancer treatment. Our findings showed that stromal re-
modeling, accompanied by upregulation of EGFR signal-
ing, is correlated with mammary tumor recurrence,
providing new insights into the development of targeted
therapies. The observation that combinatorial treatment
resulted in delayed recurrence, but no difference in pri-
mary tumor regression, suggests that there also is a need
for additional markers to evaluate neoadjuvant therapy ef-
ficacy besides pathologic complete response.
Additional files
Additional file 1: Table S1. List of antibodies and reagents. (PDF 33 kb)
Additional file 2: Figure S1. BGJ398 treatment in Wnt1/iR1 tumors
results in rapid apoptosis of luminal cells and downregulation of protein
translation pathways. A. Immunofluorescence double staining of K5 (red)
and K8 (green) in tumors from control or treatment groups (48 hours
after BGJ398 treatment). Yellow arrows indicate the areas of apoptosis.
Nuclear staining is shown in blue (DAPI). B. Immunoblot analysis of
p-mTOR and p-4E BP1 in Wnt1/iR1 tumors with BGJ398 treatment.
Beta-actin was used as a loading control. C. Protein expression levels in
Wnt1/iR1 tumors 6 and 24 hours after treated with BGJ398 as compared
to control determined through RPPA analysis. (TIF 18070 kb)
Additional file 3: Figure S2. Initial tumor size, extended BGJ398
treatment, and dimerizer injection have no significantly effect on tumor
recurrence. A. Timing of tumor regression and recurrence for individual
Wnt1/iR1 tumors from two groups of tumors with different starting sizes.
B. Analysis of starting sizes of Wnt1/iR1 tumors for BGJ398 treatment
(n = 3); **p < 0.01. Values are shown as mean ± SEM. C. Analysis of
recurrent latency between two groups with different starting sizes (n = 3);
p = 0.78. D. Timing of tumor regression and recurrence for individual
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Wnt1/iR1 tumors from two groups of tumors with different treatment
regimens (10 vs. 20 days). E. Analysis of recurrence latency (n = 5);
p = 0.89. F. Analysis of body weight loss. G. Timing of tumor regression
and recurrence for individual Wnt1/iR1 tumors receiving dimerizer
injection during dormancy or not. H. Analysis of recurrence latency
(n = 3); p = 0.6.
(TIF 22648 kb)
Additional file 4: Figure S3. Tumors recur much faster in the third
recurrence as compared to the first and second recurrences. A. Scheme
for BGJ398 treatment and tumor recurrence (third recurrence). B. Timing
of tumor regression and recurrence for individual Wnt1/iR1 tumors. C.
Comparison of the recurrence latency between the first, the second and
the third recurrences. Latency is calculated from the day of BGJ398
withdrawal to the day when the recurrent tumors reached 100 mm3
(n = 3); **p < 0.001. (TIF 21045 kb)
Additional file 5: Figure S4. Recurrent tumors eventually develop
resistance and become more invasive. A. Timing of tumor resistance for
individual Wnt1/iR1 tumors. Red arrows indicate when resistance occurred
during treatment. B. Immunofluorescence double staining of K5 (red) and
K8 (green) in primary, first and second recurrent and resistant tumors.
(TIF 1845 kb)
Additional file 6: Figure S5. Recurrent tumors are derived from the
original transplanted tumor cells and have increased proliferation. A.
Immunofluorescence staining of Ki67 in primary, first and second recurrent
tumors. Nuclear staining is shown in blue (DAPI). B. Quantification of
Ki67-positive cells in primary, first recurrent and second recurrent tumors.
(n = 4); **p < 0.01. Values are shown as mean ± SEM. C. Immunofluorescence
double staining of K5 (green) and HA (red) in recurrent tumors. Nuclear
staining is shown in blue (DAPI) in all panels. D. Immunofluorescence
double staining of K8 (green) and HA (red) in recurrent tumors. Nuclear
staining is shown in blue (DAPI) in all panels. (TIF 2877 kb)
Additional file 7: Figure S6. The number of S100A8-positive cells is
positively correlated with the number of Gr1+CD11bhigh cells. A.
Immunofluorescence staining of S100A8 in Wnt1 and Wnt1/iR1
tumors. Nuclear staining is shown in blue (DAPI). B. FACS analysis
of peripheral blood Gr1 + CD11bhigh subpopulation in control
(no tumor), Wnt1 tumor and Wnt1/iR1 tumor mouse models.
(TIF 14790 kb)
Additional file 8: Figure S7. Lapatinib treatment reduces collagen
expression in the tumor stroma. A. H&E of tumors from control or
treatment groups with 8 days of lapatinib treatment. B. Trichrome
staining of tumors from control or treatment groups with 8 days of
lapatinib treatment. C. Quantification of percentage of collagen in tumors
from control and 8-day lapatinib treatment group; ***p < 0.001. Values
are shown as mean ± SEM. D. Immunoblot analysis of p-ErbB2 in primary
Wnt1/iR1 tumors, recurrent tumors arising from BGJ398 treatment or
BGJ398 + lapatinib treatment, and tumors treated with lapatinib for 8 days.
SKBR3 cell lysate was used as a positive control for p-ErbB2. Beta-actin
was used as a loading control. E. Immunoblot analysis of p-EGFR (Y1068)
in Wnt1/iR1 tumors treated with lapatinib for 8 days, as well as recurrent
tumors arising from BGJ398 treatment or BGJ398 + lapatinib treatment, as
compared to control group treated with vehicle. Beta-actin was used as a
loading control. (TIF 32982 kb)
Additional file 9: Figure S8. Individual plots of tumor regression and
recurrence in the BGJ398 and BGJ398 and lapatinib treatment groups. Six
mice in the single BGJ398 treatment group, eight mice in the combined
BGJ398 and lapatinib treatment group, 14 mice in total. (TIF 13485 kb)
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